Skip to content
EbolaIntel
EN FR

Where it is unfolding

Active outbreak map

Open full map →

Click any point for case detail and a link to the briefing page. Cross-border spread shown for Kampala, Uganda. Tiles: OpenStreetMap + CARTO. No third-party tracking.

The one thing to know today

The current outbreak is Bundibugyo virus. No approved vaccine works against it.

The two FDA-approved Ebola vaccines - Merck’s Ervebo and the Janssen Zabdeno + Mvabea regimen - both target Zaire ebolavirus glycoprotein only. The two approved monoclonal antibody therapeutics - Regeneron’s Inmazeb and Ridgeback’s Ebanga - do the same. None of these products have demonstrated efficacy against Bundibugyo virus.

That detail is buried in product labels and WHO technical documents. It changes what an effective response can look like. Ring vaccination, the cornerstone of the 2018–2020 Kivu response, is not directly transferable here without an investigational product.

See the full matrix Bundibugyo strain profile

Latest coverage

What's been reported

All news →

Approved-product compatibility matrix

View full matrix →
Approved product Type EBOV SUDV BDBV TAFV
Ervebo Vaccine ● ○ ○ ○
Zabdeno + Mvabea Vaccine ● ○ ○ ○
Inmazeb Therapeutic ● ○ ○ ○
Ebanga Therapeutic ● ○ ○ ○

● = covered by an approved product · ○ = not covered by any approved product (as of May 2026)

Strain reference

All strains →

Zaire virus

EBOV

Discovered 1976 · 15 outbreaks

Historical CFR 40–90%. Approved vaccine available.

Sudan virus

SUDV

Discovered 1976 · 8 outbreaks

Historical CFR 40–70%. No approved vaccine.

Bundibugyo virus

BDBV

Discovered 2007 · 3 outbreaks

Historical CFR 25–51%. No approved vaccine.

Taï Forest virus

TAFV

Discovered 1994 · 1 outbreak

Single-case record; no CFR range. No approved vaccine.

Reference

Outbreak history since 1976

Every recognised ebolavirus outbreak from the 1976 Yambuku and Nzara index events through the active 2026 PHEIC. Strain, location, case and death counts, and notes - each row sourced.

Clinical

Symptoms and differential diagnosis

Early dry-phase versus progressive wet-phase symptoms. How Ebola presentation overlaps with malaria, typhoid, Lassa, Marburg, and dengue - and when to seek urgent care.

Editorial policy

Why this site exists, and how we report

Ebola is a topic where misinformation kills. During the 2014–2016 West Africa epidemic, claims about transmission routes, vaccine availability, and outbreak severity routinely diverged from primary sources. Search engines made the divergence worse. We built EbolaIntel to be the page that gets the basic facts right, with every claim traceable to a primary source.

Numbers come from WHO Disease Outbreak News, WHO AFRO, Africa CDC, and CDC Emerging Infectious Diseases. Vaccine and therapeutic claims trace to FDA and EMA records. Where we cannot confirm a number, we say so. The site is operated from Germany; no tracking, no cookies, GDPR baseline by default.

Methodology Source ledger About the editor